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Background: Cyclophosphamide (Cy) is a prodrug met-
abolized by hepatic cytochrome p450 enzymes into active
cytotoxin. High dose Cy-containing chemotherapy followed
by autologous hematopoietic cell transplant (autoHCT) is
often curative for patients with lymphoma; however, relapse
occurs in about 50% of patients. We investigated the associ-
ation between genetic polymorphisms in Cy metabolism and
outcomes after autoHCT for lymphoma.
Material and Method: We studied lymphoma patients
who received myeloablative Cy-containing conditioning be-
tween 2004-2012 with available DNA samples. Somatic DNA
was obtained from pre-transplant bone marrow aspirates,
and Sequenom and Taqman genotyping assays were used
to analyze 22 genes and 38 single nucleotide polymorphisms
(SNP) involved in Cy metabolism. All patients were followed
for at least one year. The association of each SNP with overall
survival (OS) and disease-free survival (DFS) following
autoHCT was analyzed using multivariable Cox regression,
with categorical factors for genotype, age ( 55 vs.
< 55 years), and gender. A separate model was used for each
SNP. P-values were corrected for multiple testing using the
Holm method.
Results: We studied 93 patients (median age 45 years) with
lymphoma (52 Hodgkin, 21 diffuse large B cell, 12 mantle
cell, 8 others); 55% were male. Two-thirds received Cy
(120 mg/kg) combined with BCNU/etoposide conditioning
and a third received Cy (6000 mg/ m2) with total body
irradiation (1250 cGy). The majority (96%) had chemo-
sensitive disease with 61% in complete remission pretransplant. Two year DFS and OS for the entire cohort was
60% (95%CI 49-69%) and 86% (95%CI 76-91%), respectively. A
single SNP rs3211371 in the CYP2B6 gene signiﬁcantly
impacted survival. This SNP results in Arg487Cys and
inﬂuences CYP2B6 activity. Adjusted for age and gender,
patients heterozygous (CT; n¼69) for SNP rs3211371 had
signiﬁcantly better DFS (HR 0.27; 95%CI 0.13- 0.56 ; p¼0.024)
and OS ( HR 0.09; 95%CI: 0.02-0.35; p¼0.03) as compared to
homozygous patients (TT; n¼21). This association was not
confounded by age, gender, disease type, conditioning, or
remission status.
Conclusion: Our results show a strong association between
CYP2B6 rs3211371 SNP and survival in lymphoma patients
treated with high-dose Cy and autoHCT. We plan to evaluate
serum levels of Cy active metabolites and conﬁrm the
potency of this association in a larger study.
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Introduction: High-dose therapy with AutoHCT is a
standard component of therapy for many patients with
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma
(NHL). Choice of high-dose therapy regimens has historically
been driven by institutional tradition. No randomized
prospective clinical trials have shown a difference in out-
comes between conditioning regimens.
Methods: Using the Center for International Bone Marrow
Transplant Registry (CIBMTR), we studied 4,917 patients
with lymphoma (NHL n¼3,905; HL n¼ 1,012) who under-
went AutoHCT from 1995-2008 using the most commonly
used conditioning regimens: BEAM (n¼1730), CBVlow
(n¼1249), CBVhigh (n¼604), BuCy (n¼789), and TBI (n¼545)-
based regimens. The CBV cohort was divided based on
the BCNU dose and its impact on outcome (above [high] vs.
below [low] 375 mg/m2).
Results: The cohorts differed in: age <54y (BEAM 47%,
CBVlow 61%, CBVhigh 66%, BuCy 50% and TBI 60%), HL (BEAM
18%, CBVlow 23%, CBVhigh 37%, BuCy 21% and TBI 4%) and year
of transplant 2002 (BEAM 70%, CBVlow 18%, CBVhigh 26%,
BuCy 49% and TBI 19%). 1-year rates of TRM ranged from 4%
